Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.

[cafead]

via

• The Food and Drug Administration recently approved Kisunla as a treatment for early symptomatic Alzheimer's disease.
• Despite the news, shares of Eli Lilly didn't take off.
• Much of the enthusiasm behind the stock centers around its promising weight loss and diabetes products.

article source